Stem cell injection and lymphedema

Phase 2

• Conditions: Idiopathic lymphedema.; Lymphedema, not elsewhere classified; I89.0

• Registration Number: IRCT20191019045155N4
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 April 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

Age between 10 to 35 years old
Lower limb edema
Age of onset less than 35 years old
Duration of diagnosis more than 72 hours
Grade less than III
Sub-classification of less than 3b
Informed consent to enter the study

Exclusion Criteria

Heart failure
Renal failure
Hepatic failure
History of related surgery (lymph node dissection)
History of pelvic malignancy or treatment for malignancy (irradiation)
Autoimmune disease
History of trauma or infection,
Symptoms of sleep apnea,
Previous bone marrow transplant,
Morbid obesity > 40 kg/m2
Lipoedema
Allergic disorder
Cytotoxic drugs
Drugs induced lymphedema,
Congenital vascular malformation
Myxedema
Traveling to tropical countries or suspicion to filariasis

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Volume of edema in lower extremities. Timepoint: The patients were visited 2 and 6 months post-operation. Method of measurement: Limb circumference and water displacement method.